A US Food and Drug Administration initiative has sped the review and approval process for promising drugs, but researchers from Wake Forest University Medical School note in the Journal of the American Medical Association that some fast-tracked drugs have been associated with safety risks. Thomas Moore and Curt Furberg focus on three drugs — vandetanib, fingolimod, and dabigatran — that have been approved quickly despite some safety concerns and uncertainty regarding dosing.